** Shares of Terns Pharmaceuticals rise ~6% to $6.5 premarket
** Co says its experimental drug to treat a type of blood cancer showed clinically meaningful responses in patients at two lowest dose levels
** The drug, TERN-701, showed no dose-limiting toxicities across three completed dose levels, and no side-effect-related dose reductions or discontinuations - TERN
** TERN plans to share additional safety and efficacy data in late 2025
** The initial data was above expectations and supported long-term use, according to BMO Capital analysts
** TERN-701 is being developed to treat heavily pre-treated patients with relapsed/refractory chronic myeloid leukemia
** Up to last close, shares down ~5% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。